These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Association between mammographic density and basal-like and luminal A breast cancer subtypes. Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056 [TBL] [Abstract][Full Text] [Related]
5. Triple-negative breast cancer: current state of the art. Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S Tumori; 2010; 96(6):875-88. PubMed ID: 21388048 [TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of triple-negative breast cancer. Arslan C; Dizdar O; Altundag K Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211 [TBL] [Abstract][Full Text] [Related]
7. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features. Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513 [TBL] [Abstract][Full Text] [Related]
8. p16INK4a expression in basal-like breast carcinoma. Bohn OL; Fuertes-Camilo M; Navarro L; Saldivar J; Sanchez-Sosa S Int J Clin Exp Pathol; 2010 Jun; 3(6):600-7. PubMed ID: 20661408 [TBL] [Abstract][Full Text] [Related]
9. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer]. Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221 [TBL] [Abstract][Full Text] [Related]
10. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Karihtala P; Auvinen P; Kauppila S; Haapasaari KM; Jukkola-Vuorinen A; Soini Y Breast Cancer Res Treat; 2013 Feb; 138(1):81-90. PubMed ID: 23412770 [TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Kreike B; van Kouwenhove M; Horlings H; Weigelt B; Peterse H; Bartelink H; van de Vijver MJ Breast Cancer Res; 2007; 9(5):R65. PubMed ID: 17910759 [TBL] [Abstract][Full Text] [Related]
12. Triple negative breast cancers: clinical and prognostic implications. Dawson SJ; Provenzano E; Caldas C Eur J Cancer; 2009 Sep; 45 Suppl 1():27-40. PubMed ID: 19775602 [TBL] [Abstract][Full Text] [Related]
13. MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Siroy A; Abdul-Karim FW; Miedler J; Fong N; Fu P; Gilmore H; Baar J Hum Pathol; 2013 Oct; 44(10):2159-66. PubMed ID: 23845471 [TBL] [Abstract][Full Text] [Related]
14. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Thike AA; Cheok PY; Jara-Lazaro AR; Tan B; Tan P; Tan PH Mod Pathol; 2010 Jan; 23(1):123-33. PubMed ID: 19855377 [TBL] [Abstract][Full Text] [Related]
15. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Sharpe R; Pearson A; Herrera-Abreu MT; Johnson D; Mackay A; Welti JC; Natrajan R; Reynolds AR; Reis-Filho JS; Ashworth A; Turner NC Clin Cancer Res; 2011 Aug; 17(16):5275-86. PubMed ID: 21712446 [TBL] [Abstract][Full Text] [Related]
16. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers. Reyes C; Jorda M; Gomez-Fernández C Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826 [TBL] [Abstract][Full Text] [Related]
17. Basal breast cancer: a complex and deadly molecular subtype. Bertucci F; Finetti P; Birnbaum D Curr Mol Med; 2012 Jan; 12(1):96-110. PubMed ID: 22082486 [TBL] [Abstract][Full Text] [Related]
18. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Fadare O; Tavassoli FA Adv Anat Pathol; 2007 Sep; 14(5):358-73. PubMed ID: 17717437 [TBL] [Abstract][Full Text] [Related]
19. p53 status identifies two subgroups of triple-negative breast cancers with distinct biological features. Biganzoli E; Coradini D; Ambrogi F; Garibaldi JM; Lisboa P; Soria D; Green AR; Pedriali M; Piantelli M; Querzoli P; Demicheli R; Boracchi P; Nenci I; Ellis IO; Alberti S Jpn J Clin Oncol; 2011 Feb; 41(2):172-9. PubMed ID: 21199790 [TBL] [Abstract][Full Text] [Related]
20. Novel targets for triple-negative breast cancer. Carey LA Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512 [No Abstract] [Full Text] [Related] [Next] [New Search]